Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer
Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer
批准号:
8301002
负责人:
Jean Zhao
金额:
$32.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-26 至 2013-07-31
关键词:
1-Phosphatidylinositol 3-KinaseAblationAdverse effectsAnimal ModelBiologicalBiological ProcessBreast Cancer TreatmentCell Culture TechniquesCell ProliferationCell physiologyCellsColon CarcinomaDataDevelopmentDrug Delivery SystemsERBB2 geneEmbryoEpithelialEpithelial CellsEventFibroblastsGenesGenetic RecombinationGoalsGrowthHumanInterventionKnock-outKnockout MiceKnowledgeLactationLipidsMalignant NeoplasmsMalignant neoplasm of brainMammalsMammary Gland ParenchymaMammary NeoplasmsMammary glandMediatingModelingMolecular StructureMouse Mammary Tumor VirusMusOncogenicOrganPIK3CA genePIK3CB genePTEN genePathogenesisPathway interactionsPharmaceutical PreparationsPhosphoric Monoester HydrolasesPhysiologicalPlayProtein IsoformsProteinsPublic HealthReceptor Protein-Tyrosine KinasesRelative (related person)ResearchRiskRoleSignal PathwaySignal TransductionSiteSomatic MutationStagingSystemTestingTherapeutic InterventionTissuesTransgenic OrganismsTumor Suppressor ProteinsTumor-Derivedabstractingbreast tumorigenesiscancer therapygland developmentkinase inhibitorknockout animalmalignant breast neoplasmmammary epitheliummammary gland developmentoverexpressionphosphatidylinositol 3,4,5-triphosphateresponsetumortumor initiationtumorigenesiswortmannin
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Roles of class 1A PI3K isoforms in mammary epithelium function and breast
cancer
Abstract Section
a. Summary
Class IA phosphatidylinositol 3-kinases (PI3Ks) are activated by growth factor receptor
tyrosine kinases (RTKs) and Ras to generate the primary intracellular lipid signal,
phosphatidylinositol 3,4,5-trisphosphate (PIP3), essential for multiple cellular processes,
including survival, proliferation and differentiation. The tumor suppressor PTEN, a lipid
phosphatase, dephosphorylates PIP3 and therefore counteracts the action of PI3Ks.
Constitutive activation of the class IA PI3K signaling pathway via direct or indirect
mutagenic events is amongst the most frequent events in human breast cancer. Thus,
class 1A PI3Ks are attractive targets for therapeutic intervention in breast cancer. In
mammals, there are two class 1A PI3K catalytic isoforms, p110¿ and p110¿, which are
ubiquitously expressed in epithelial tissues/organs, among other sites. Despite their
similarity in molecular structure and enzymatic activity, recent studies suggest that the
two isoforms have distinct functions in cell signaling and oncogenic transformation.
However, we have very limited understanding of the specific functions for each type of
PI3K. All class IA PI3Ks display the same sensitivity to the classical PI3K inhibitors
wortmannin and LY294002. Mice lacking p110¿ or p110¿ are early embryonic lethal,
which precluded further delineation of their specific functions. We recently generated
conditional knockout animals for the p110¿ and p110¿ genes via the Cre/loxP
recombination system to facilitate the study of class 1A PI3Ks. In this application, we
want to test our hypothesis that p110¿ and p110¿ have distinct biological roles in
mammary epithelium function and tumorigenesis. This hypothesis leads to predictions
that we propose to test in cell culture and animal models. The Specific Aims are as
follows.
1. To test the prediction that p110¿ and p110¿ have distinct roles in signal transduction
and cell proliferation in mouse mammary epithelial cells (MMECs).
2. To test the prediction that p110¿ and p110¿ have distinct roles in mammary gland
development.
3. To test the prediction that p110¿ and p110¿ have distinct functions in breast
tumorigenesis driven by oncogenic Her2/Neu.
These studies will advance our understanding of the functions of PI3K isoforms and
provide information critical to developing effective, specific and less toxic PI3K inhibitors
for cancer treatment. b. Relevance to Public Health
The Class IA PI3K signaling pathway is hyper-activated in a high percentage of human
cancers, including breast, brain and colon cancers, and is also highly suited for
pharmacologic intervention. However, because PI3K activity is involved in multiple
fundamental physiological functions, there is a considerable risk that its inhibition may
have toxic side effects. The information derived from this study will not only provide us
with comprehensive knowledge of PI3K isoforms in normal breast tissue function and
tumor pathogenesis, but will also help us to evaluate critical drug targets to facilitate the
development of more specific and less toxic drugs for breast cancer treatment.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Therapeutic implications of GIPC1 silencing in cancer.
GIPC1沉默在癌症中的治疗意义。
DOI:
10.1371/journal.pone.0015581
发表时间:
2010-12-30
期刊:
PloS one
影响因子:
3.7
作者:
[Chittenden TW, Pak J, Rubio R, Cheng H, Holton K, Prendergast N, Glinskii V, Cai Y, Culhane A, Bentink S, Schwede M, Mar JC, Howe EA, Aryee M, Sultana R, Lanahan AA, Taylor JM, Holmes C, Hahn WC, Zhao JJ, Iglehart JD, Quackenbush J]
通讯作者:
Quackenbush J
Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration
-
批准号:10697498
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2023
-
负责人:Jean Zhao
-
依托单位:
Integrating targeted therapy and immunotherapy to break through cancer
-
批准号:10737039
-
项目类别:
-
资助金额:$102.76万
-
财政年份:2016
-
负责人:Jean Zhao
-
依托单位:
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
-
批准号:9186720
-
项目类别:
-
资助金额:$77.58万
-
财政年份:2016
-
负责人:Jean Zhao
-
依托单位:
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
-
批准号:9763524
-
项目类别:
-
资助金额:$97.7万
-
财政年份:2016
-
负责人:Jean Zhao
-
依托单位:
Developing novel targeted therapeutics integrated with immunotherapy-based approaches to make breakthroughs in metastatic breast cancer
-
批准号:10240658
-
项目类别:
-
资助金额:$100.72万
-
财政年份:2016
-
负责人:Jean Zhao
-
依托单位:
Targeting the p110beta Isoform of PI3 Kinase in Pten Null Tumors
-
批准号:8419866
-
项目类别:
-
资助金额:$41.36万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)
-
批准号:10019491
-
项目类别:
-
资助金额:$35.88万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Project 3: Improving therapeutic approaches for breast cancer brain metastases
-
批准号:10215415
-
项目类别:
-
资助金额:$30.51万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Targeting the p110beta Isoform of PI3 Kinase in Pten Null Tumors
-
批准号:8986642
-
项目类别:
-
资助金额:$41.36万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)
-
批准号:10268490
-
项目类别:
-
资助金额:$26.4万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Targeting the p110beta Isoform of PI3 Kinase in Pten Null Tumors
-
批准号:8601056
-
项目类别:
-
资助金额:$40.12万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Project 3: Improving therapeutic approaches for breast cancer brain metastases
-
批准号:10668345
-
项目类别:
-
资助金额:$27.71万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)
-
批准号:10696102
-
项目类别:
-
资助金额:$30.35万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Project 3: Improving therapeutic approaches for breast cancer brain metastases
-
批准号:10455692
-
项目类别:
-
资助金额:$26.36万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Targeting the p110beta Isoform of PI3 Kinase in Pten Null Tumors
-
批准号:8785104
-
项目类别:
-
资助金额:$41.36万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)
-
批准号:10245087
-
项目类别:
-
资助金额:$35.37万
-
财政年份:2013
-
负责人:Jean Zhao
-
依托单位:
Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer
-
批准号:7693820
-
项目类别:
-
资助金额:$33.5万
-
财政年份:2008
-
负责人:Jean Zhao
-
依托单位:
Roles of class 1A PI3K isoforms in mammary epithelium function and breast cancer
-
批准号:8111909
-
项目类别:
-
资助金额:$32.5万
-
财政年份:2008
-
负责人:Jean Zhao
-
依托单位:
Project 3 - Targeting CDK4/6 to modulate immunogenicity in gliomas (Wen/Zhao)
-
批准号:10013540
-
项目类别:
-
资助金额:$32.33万
-
财政年份:--
-
负责人:Jean Zhao
-
依托单位:
海外基金